Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An update from InMed Pharmaceuticals ( (INM) ) is now available.
InMed Pharmaceuticals has announced the granting of an international Patent Cooperation Treaty (PCT) patent in Mexico for a family of novel small molecule compounds, marking the first jurisdictional issuance of this patent. This new patent protects cannabinoid analogs and methods of their preparation, enhancing InMed’s intellectual property portfolio and supporting the development of innovative drug candidates for Alzheimer’s disease and age-related macular degeneration. This development underscores InMed’s commitment to intellectual property protection and its focus on expanding its patent portfolio, which is crucial for the company’s operations and positioning in the pharmaceutical industry. The PCT patent has been filed in several other jurisdictions, including the U.S., Europe, and Japan, highlighting the company’s strategic efforts to secure long-term protection for its novel drug candidates.
More about InMed Pharmaceuticals
InMed Pharmaceuticals Inc. is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs. The company’s research primarily targets therapeutic applications in areas such as pain, glaucoma, inflammatory diseases, anxiety, and various neurological conditions including Parkinson’s disease, Alzheimer’s disease, and dementia.
YTD Price Performance: 5.21%
Average Trading Volume: 471,891
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.66M
Learn more about INM stock on TipRanks’ Stock Analysis page.
